Year: 2024

The Company achieved numerous commercial milestones in 2024, including increased profitability, launching an initial public offering, moving into new marketplaces, securing key strategic acquisitions and partnerships, and finalizing landmark carbon offset presales FORT LAUDERDALE, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) — ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the “Company”, “Zefiro”, or “ZEFI”), an environmental services company specializing in methane abatement operations, took numerous steps in 2024 to accelerate the Company’s profitability and commercial momentum. Specifically, Zefiro’s success over the past twelve months can be attributed to its execution of the Company’s strategy to expand its commercial footprint in critical marketplaces across North America and generate industry-leading,...

Listing:         TSX (Toronto Stock Exchange) Symbol:         CMR TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE: BLK) announced on November 8, 2024, that it called a special meeting of unitholders (the “Meeting”) of the iShares Premium Money Market ETF (the “iShares Fund”), to originally be held on or about January 22, 2025 to approve a change to the investment objective of the iShares Fund to permit investments in asset-backed commercial paper (the “Proposal”). As a result of the Canada Post labour disruption, BlackRock Canada is postponing the Meeting to February 3, 2025. BlackRock Canada is holding the Meeting solely as a virtual (online) meeting by way of live audio webcast.   In accordance...

Filing follows successful completion of the independent audit for the year ended 30 June 2024 Prior non-compliance with NASDAQ listing requirements due to delayed filing has been remedied LONDON, Dec. 19, 2024 (GLOBE NEWSWIRE) — On December 19, 2024, VivoPower International PLC (Nasdaq: VVPR) (“VivoPower” or the “Company”) filed its 2024 Annual Report on Form 20-F. This follows the successful completion of the independent audit for the year ended 30 June 2024. As a result of this filing, the Company has rectified a prior non-compliance with listing requirements of the Nasdaq Stock Market (“Nasdaq”), including Listing Rule 5250(c)(1). The delay in the filing of the Form 20-F was due to the number of significant strategic changes to the Company, including the divestiture of business units. About...

SANTA CLARA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco”), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today announced that the U.S. Court of Appeals for the Ninth Circuit affirmed the U.S. District Court for the Northern District of California’s dismissal of all claims against Silvaco brought by Aldini AG. “We are pleased with the court’s decision,” said Babak Taheri, CEO of Silvaco. “This outcome validates our commitment to integrity. With this matter resolved, we can dedicate our full attention to what truly matters: empowering our customers and driving innovation in the industry.” About Silvaco Silvaco is a provider of TCAD, EDA software and...

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx’s intellectual property portfolio highlights the Company’s commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensis, Ganoderma lucidum (Reishi), and Hericium erinaceus (Lion’s Mane). These formulations are designed to deliver a range of health benefits, such...

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured patients across the country. neffy 2 mg is for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh...

HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific”) today announced its 2025 capital expenditure and turnaround outlay guidance with a range of $210 million to $240 million.  2025 Capital Expenditure and Turnaround Outlay Guidance$ in millions     Turnarounds & Catalyst $85 – 95Maintenance 1 75 – 85Growth 2 50 – 60Total Capital Expenditure and Turnaround Outlay $210 – 240Includes approximately $10 million in reliability investments. Includes approximately $30-40 million to complete the Hawaii renewable hydrotreater project and $10 million in ERP system enhancements.Management expects 2024 capital expenditures and turnaround outlays to come in at the low end of the $220 million to $250 million guidance range. About Par Pacific Par...

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) is pleased to announce that today a partial final award (the “Award”) was made by the three-member international arbitration Tribunal appointed in connection with the Company’s binding arbitration proceedings against its joint venture partner Oyu Tolgoi LLC (“OTLLC”) and Turquoise Hill Resources Ltd. (together, the “Respondents”). The Tribunal has ruled in favor of Entrée on all issues and dismissed the Respondents’ counterclaims. Stephen Scott, the Company’s President & CEO commented, “This Award represents a tremendous outcome for the Company and provides much needed certainty for all Oyu Tolgoi project stakeholders as we endeavor to keep Lift 1 Panel 1 development work on schedule.” The...

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV:XGC) (“Xali Gold” or the ”Company”) reports that, pursuant to the terms and conditions of its Omnibus Equity Incentive Plan, an aggregate of 4,100,000 stock options to purchase common shares of the Company have been granted to certain directors, officers and consultants of the Company. The options are exercisable for a period of five years at a price of $0.05 per share. Xali Gold is pleased to announce the results of the Company’s Annual General Meeting of Shareholders (the “Meeting”) held on December 19th, 2024. A total of 14,006,597 common shares of the Company were voted at the meeting, representing 9.83% of the total number of issued and outstanding shares of the Company. At the Meeting, all five director nominees listed in the Company’s...

LOS ANGELES, Dec. 19, 2024 (GLOBE NEWSWIRE) — Preferred Bank (NASDAQ: PFBC), (“the Bank”), an independent commercial bank, today announced that the Bank had uncovered an unreconciled difference in its calculation of its right of use asset (“ROU”) and lease liabilities. As a result of this error, the Bank will record $8.1 million on a pre-tax basis of occupancy expense in the fourth quarter of 2024. On an after-tax basis, this will reduce fourth quarter diluted earnings per share by approximately $0.43. In January of 2019, the Bank adopted ASC 842, Accounting for Leases. This accounting statement requires entities capitalize leases that are longer than one year. The effect being that lease expense is recognized more evenly over the life of the lease, rather than recording lease expense as incurred. When the Bank adopted ASC 842,...